QLGN News and Press, Qualigen Therapeutics Inc. From 07/06/22

CARLSBAD, Calif., July 06, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, while also commercializing diagnostics, today anno...

Qualigen Therapeutics (NASDAQ:QLGN) on Friday has filed for the secondary stock offering of its 8,161,312 common shares. It will comprise of 3,500,000 shares and 4,661,312 shares purchase warrants, exercisable to purchase shares of common stock. The biotech company made it clear it will not r...

CARLSBAD, Calif., June 14, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, while also commercializing diagnostics, today anno...

Qualigen Therapeutics (NASDAQ:QLGN -1.6%) said on Tuesday it had begun IND-enabling studies for its lead program, QN-302, to treat pancreatic cancer, and potentially prostate cancer and other solid tumors. The company said its Investigational New Drug, or IND-enabling...

A P otential T reatment for Pancreatic Cancer in A ddition to O ther T umors of H igh U nmet C linical N eed CARLSBAD, Calif., June 07, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLG...

Qualigen Therapeutics (NASDAQ:QLGN) stock rose June 2 after the company said it completed the acquisition of a majority stake in Israeli diagnostics company NanoSynex. Qualigen said NanoSynex's technology is an Antimicrobial Susceptibility Testing (AST) platform that aims to provide accu...

Transaction expected to significantly advance commercial readiness of Nano S ynex’ s innovative diagnostic s technology platform focused on the $30+ Billion global infectious disease testing market Compan...

Abstracts Highlight In Vitro and In Vivo Activity of Qualigen’s Pan-RAS inhibitor in (1) Pancreatic Cancer, and (2) Malignant Peripheral Nerve Sheath Tumors CARLSBAD, Calif., May 26, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a diversified life scien...

CARLSBAD, Calif., May 20, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, while also commercializing diagnostics, today annou...

Qualigen Therapeutics press release (NASDAQ:QLGN): Q1 GAAP EPS of -$0.12 beats by $0.07. Revenue of $0.72M (-62.1% Y/Y) misses by $0.14M. As of March 31, 2022, Qualigen Therapeutics had $13.6 million in cash For further details see: Qualigen Therapeutics GAAP EPS of -$0.12 beats by $0.0...